A Phase 1 Clinical Trial of Satralizumab as a Treatment for Aneurysmal Subarachnoid Hemorrhage
Latest Information Update: 20 Aug 2024
At a glance
- Drugs Satralizumab (Primary)
- Indications Subarachnoid haemorrhage
- Focus Adverse reactions
- Acronyms SASH
Most Recent Events
- 13 Aug 2024 Status changed from not yet recruiting to suspended.
- 07 May 2024 Planned initiation date changed from 1 Jun 2024 to 1 Jul 2024.
- 09 Apr 2024 Planned initiation date changed from 1 Mar 2024 to 1 Jun 2024.